Search

Your search keyword '"Tural, Cristina"' showing total 231 results
Start Over Author "Tural, Cristina" Language english
231 results on '"Tural, Cristina"'

2. HLA-B*57 and IFNL4-Related Polymorphisms Are Associated With Protection Against HIV-1 Disease Progression in Controllers

Author

Spanish AIDS Research Network HIV-Controllers Cohort integrated in the Spanish AIDS Research Network, Dominguez-Molina, Beatriz, Tarancon-Diez, Laura, Hua, Stephane, Abad-Molina, Cristina, Rodriguez-Gallego, Esther, Machmach, Kawthar, Vidal, Francesc, Tural, Cristina, Moreno, Santiago, Goñi, Maria José, de Arellano, Elena Ramírez, del Val, Margarita, Gonzatez-Escribano, Maria Francisca, Del Romero, Jorge, Rodriguez, Carmen, Capa, Laura, Viciana, Pompeyo, Alcami, José, Yu, Xu G., Walker, Bruce D., Leal, Manuel, Lichterfeld, Mathias, and Ruiz-Mateos, Ezequiel

Published
2017

3. ADAR1 function affects HPV replication and is associated to recurrent human papillomavirus-induced dysplasia in HIV coinfected individuals

Author

Pujantell, Maria, Badia, Roger, Galván-Femenía, Iván, Garcia-Vidal, Edurne, de Cid, Rafael, Alcalde, Carmen, Tarrats, Antonio, Piñol, Marta, Garcia, Francesc, Chamorro, Ana M., Revollo, Boris, Videla, Sebastian, Parés, David, Corral, Javier, Tural, Cristina, Sirera, Guillem, Esté, José A., Ballana, Ester, and Riveira-Muñoz, Eva

Published
2019
Full Text
View/download PDF

4. Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection

Author

Nicolás, David, Esteve, Anna, Cuadros, Anna, Campbell, Colin N. J., Tural, Cristina, Podzamczer, Daniel, Murillas, Javier, Homar, Francesc, Segura, Ferrán, Force, Lluis, Vilaró, Josep, Masabeu, Àngels, Garcia, Isabel, Mercadal, Jordi, Montoliu, Alexandra, Ferrer, Elena, Riera, Melcior, Cifuentes, Carmen, Ambrosioni, Juan, Navarro, Gemma, Manzardo, Christian, Clotet, Bonaventura, Gatell, Josep M., Casabona, Jordi, and Miró, José M.

Published
2016

6. Comparison of the Prognostic Value of Liver Biopsy and FIB-4 Index in Patients Coinfected With HIV and Hepatitis C Virus

Author

Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group, Berenguer, Juan, Zamora, Francisco X., Aldámiz-Echevarría, Teresa, Von Wichmann, Miguel A., Crespo, Manel, López-Aldeguer, José, Carrero, Ana, Montes, Marisa, Quereda, Carmen, Téllez, María J., Galindo, María J., Sanz, José, Santos, Ignacio, Guardiola, Josep M., Barros, Carlos, Ortega, Enrique, Pulido, Federico, Rubio, Rafael, Mallolas, Josep, Tural, Cristina, Jusdado, Juan J., Pérez, Gloria, Díez, Cristina, Álvarez-Pellicer, Julio, Esteban, Herminia, Bellón, José M., and González-García, Juan

Published
2015

7. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2

Author

Rockstroh, Jürgen K, Orkin, Chloe, Viani, Rolando M, Wyles, David, Luetkemeyer, Anne F, Lazzarin, Adriano, Soto-Malave, Ruth, Nelson, Mark R, Bhagani, Sanjay R, Klinker, Hartwig H F, Rizzardini, Giuliano, Girard, Pierre-Marie, Tural, Cristina, Shulman, Nancy S, Mobashery, Niloufar, Hu, Yiran B, Fredrick, Linda M, Pilot-Matias, Tami, Trinh, Roger, and Gane, Edward

Published
2017
Full Text
View/download PDF

9. Genetic Variation in IL28B and Treatment-induced Clearance of Hepatitis C Virus in HIV-Positive Patients With Acute and Chronic Hepatitis C

Author

Nattermann, Jacob, Vogel, Martin, Nischalke, Hans Dieter, Danta, Mark, Mauss, Stefan, Stellbrink, Hans-Jörg, Baumgarten, Axel, Mayr, Christoph, Bruno, Raffaele, Tural, Cristina, Klausen, Gerd, Clotet, Bonaventura, Naumann, Uwe, Lutz, Thomas, Rausch, Michael, Schewe, Knud, Bienek, Bernhard, Haerter, Georg, Sauerbruch, Tilman, Rockstroh, Juergen K., and Spengler, Ulrich

Published
2011
Full Text
View/download PDF

12. Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status

Author

Ferrer, Elena, Curto, Jordi, Esteve, Anna, Miro, Jose M., Tural, Cristina, Murillas, Javier, Segura, Ferran, Barrufet, Pilar, Casabona, Jordi, Podzamczer, Daniel, Casabona, J., Miró, Jose M., Campbell, C. N. J., Casabona, J., Esteve, A., Campbell, C. N. J., Miró, J. M., Podzamczer, D., Murillas, J., Gatell, J. M., Manzardo, C., Tural, C., Clotet, B., Ferrer, E., Riera, M., Segura, F., Navarro, G., Force, L., Vilaró, J., Masabeu, A., García, I., Mercadal, J., Cifuentes, C., Homar, F., Dalmau, D., Jaen, À., Domingo, P., Falcó, V., Curran, A., Agustí, C., Esteve, A., Montoliu, A., Pérez, I., Curto, J., Gargoulas, F., Gómez, A., Rubia, J. C., Zamora, L., Blanco, J. L., Garcia-Alcaide, F., Martínez, E., Mallolas, J., Llibre, J. M., Sirera, G., Romeu, J., Jou, A., Negredo, E., Saumoy, M., Imaz, A., Bolao, F., Cabellos, C., Peña, C., DiYacovo, S., Van Den Eynde, E., Sala, M., Cervantes, M., Amengual, M. J., Navarro, M., Segura, V., Barrufet, P., Molina, J., Alvaro, M., Orriols, M., Payeras, T., Gracia Mateo, M., and Fernández, J.

Published
2015
Full Text
View/download PDF

13. Prevalence of Transmitted Antiretroviral Resistance and Distribution of HIV-1 Subtypes Among Patients with Recent Infection in Catalonia (Spain) between 2003 and 2005

Author

Romero, Anabel, Sued, Omar, Puig, Teresa, Esteve, Anna, Pumarola, Tomàs, Casabona, Jordi, González, Victoria, Matas, Lurdes, Tural, Cristina, Rodrigo, Isabel, Margall, Núria, Domingo, Pere, Casanova, Aurora, Ferrer, Elena, Caballero, Estrella, Ribera, Esteve, Farré, Joan, Amengual, M. José, Navarro, Gemma, Prat, Josep M., Masabeu, Àngels, Simó, Josep M., Villaverde, Carlos A., Barrufet, Pilar, Sauca, M. Goretti, Ortin, Xavier, Ortí, Amat, Navarro, Rosa, Euras, Josep M., Vilaró, Josep, Villà, M. Carme, Montull, Santiago, Vilanova, Conrad, Pujol, Ferran, Díaz, Olga, and Miró, Jose M.

Published
2010
Full Text
View/download PDF

20. Circulating MicroRNAs as a Tool for Diagnosis of Liver Disease Progression in People Living with HIV-1.

Author

Martinez, Miguel Angel, Tural, Cristina, and Franco, Sandra

Subjects
*AIDS, *REGULATION of body fluids, *DIAGNOSIS, *NON-alcoholic fatty liver disease, *DISEASE progression, *HIV
Abstract

MicroRNAs (miRNAs) are small, non-coding RNAs that post-transcriptionally regulate gene expression by binding specific cell mRNA targets, preventing their translation. miRNAs are implicated in the regulation of important physiological and pathological pathways. Liver disease, including injury, fibrosis, metabolism dysregulation, and tumor development disrupts liver-associated miRNAs. In addition to their effect in the originating tissue, miRNAs can also circulate in body fluids. miRNA release is an important form of intercellular communication that plays a role in the physiological and pathological processes underlying multiple diseases. Circulating plasma levels of miRNAs have been identified as potential disease biomarkers. One of the main challenges clinics face is the lack of available noninvasive biomarkers for diagnosing and predicting the different stages of liver disease (e.g., nonalcoholic fatty liver disease and nonalcoholic steatohepatitis), particularly among individuals infected with human immunodeficiency virus type 1 (HIV-1). Liver disease is a leading cause of death unrelated to acquired immunodeficiency syndrome (AIDS) among people living with HIV-1 (PLWH). Here, we review and discuss the utility of circulating miRNAs as biomarkers for early diagnosis, prognosis, and assessment of liver disease in PLWH. Remarkably, the identification of dysregulated miRNA expression may also identify targets for new therapeutics. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study.

Author

Batule, Sol, Ramos, Analía, Pérez-Montes de Oca, Alejandra, Fuentes, Natalia, Martínez, Santiago, Raga, Joan, Pena, Xoel, Tural, Cristina, Muñoz, Pilar, Soldevila, Berta, Alonso, Nuria, Umpierrez, Guillermo, and Puig-Domingo, Manel

Abstract

Background: The basal–bolus insulin regimen is recommended in hospitalized patients with diabetes mellitus (DM), but has an increased risk of hypoglycemia. We aimed to compare dipeptidyl peptidase 4 inhibitors (DPP4-i) and basal–bolus insulin glycemic outcomes in hospitalized type 2 DM patients. Methods and patients: Our prospective randomized study included 102 elderly T2DM patients (82 ± 9 years, HbA1c 6.6% ± 1.9). Glycemic control: A variability coefficient assessed by continuous glucose monitoring (Free Style® sensor), mean insulin dose and hypoglycemia rates obtained with the two treatments were analyzed. Results: No differences were found between groups in glycemic control (mean daily glycemia during the first 10 days: 152.6 ± 38.5 vs. 154.2 ± 26.3 mg/dL; p = 0.8). The total doses Kg/day were 0.40 vs. 0.20, respectively (p < 0.001). A lower number of hypoglycemic events (9% vs. 15%; p < 0.04) and lower glycemic coefficient of variation (22% vs. 28%; p < 0.0002) were observed in the basal–DPP4-i compared to the basal–bolus regimen group. Conclusions: Treatment of inpatient hyperglycemia with basal insulin plus DPP4-i is an effective and safe regimen in old subjects with T2DM, with a similar mean daily glucose concentration, but lower glycemic variability and fewer hypoglycemic episodes compared to the basal bolus insulin regimen. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006–08)

Author

Romero, Anabel, González, Victoria, Esteve, Anna, Martró, Elisa, Matas, Lurdes, Tural, Cristina, Pumarola, Tomàs, Casanova, Aurora, Ferrer, Elena, Caballero, Estrella, Ribera, Esteve, Margall, Núria, Domingo, Pere, Farré, Joan, Puig, Teresa, Sauca, MGoretti, Barrufet, Pilar, Amengual, MJosé, Navarro, Gemma, Navarro, Maria, Vilaró, Josep, Ortín, Xavier, Ortí, Amat, Pujol, Ferran, Prat, Josep M., Massabeu, Àngels, Simó, Josep M., Villaverde, Carlos Alonso, Benítez, Miguel Ángel, Garcia, Isabel, Díaz, Olga, Becerra, Jasmina, Ros, Rosa, Sala, Roser, Rodrigo, Isabel, Miró, José M., and Casabona, Jordi

Published
2012
Full Text
View/download PDF

31. The Changing Face of HIV/AIDS in Treated Patients

Author

Llibre, Josep M., Falco, Vicenç, Tural, Cristina, Negredo, Eugenia, Pineda, Juan A., Muñoz, Jose, Ortega, Enrique, Videla, Sebastia, Sirera, Guillem, Martinez, Esteban, Miralles, Celia, Iribarren, Josean, Galindo, Maria J., Domingo, Pere, dʼArminio-Monforte, Antonella, Miro, Jose M., and Clotet, Bonaventura

Published
2009

33. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

Author

Mira, José A., López-Cortés, Luis F., Barreiro, Pablo, Tural, Cristina, Torres-Tortosa, Manuel, Gil, Ignacio de los Santos, Martín-Rico, Patricia, Ríos-Villegas, María J., Hernández-Burruezo, José Juan, Merino, Dolores, López-Ruz, Miguel Ángel, Rivero, Antonio, Muñoz, Leopoldo, González-Serrano, Mercedes, Collado, Antonio, Macías, Juan, Viciana, Pompeyo, Soriano, Vincent, and Pineda, Juan A.

Published
2008

39. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

Author

Rockstroh, Jurgen K., Mocroft, Amanda, Soriano, Vincent, Tural, Cristina, Losso, Marcello H., Horban, Andrzej, Kirk, Ole, Phillips, Andrew, Ledergerber, Bruno, and Lundgren, Jens

Subjects
Liver diseases -- Diagnosis, Liver diseases -- Drug therapy, Hepatitis C -- Diagnosis, Hepatitis C -- Drug therapy, Antiviral agents -- Dosage and administration, Health
Published
2005

45. IFN-γ response on T-cell based assays in HIV-infected patients for detection of tuberculosis infection

Author

Tural Cristina, Puig Jordi, Font Roser, Lacoma Alicia, Martínez-Lacasa Xavier, Latorre Irene, Lite Josep, Prat Cristina, Cuchi Eva, Ausina Vicente, and Domínguez Jose

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Individuals infected with human immunodeficiency virus (HIV) have an increased risk of progression to active tuberculosis following Mycobacterium tuberculosis infection. The objective of the study was to determine IFN-γ responses for the detection of latent tuberculosis infection (LTBI) with QuantiFERON-TB GOLD In Tube (QFT-G-IT) and T-SPOT.TB in HIV patients, and evaluate the influence of CD4 cell count on tests performance. Methods We studied 75 HIV patients enrolled for ongoing studies of LTBI with T-SPOT.TB, QFN-G-IT and TST. Mean CD4 cell counts ± standard deviation was 461.29 ± 307.49 cells/μl. Eight patients had a BCG scar. Results T-SPOT.TB, QFN-G-IT and TST were positive in 7 (9.3%), 5 (6.7%) and 9 (12%) cases, respectively. Global agreement between QFN-G-IT and T-SPOT.TB was 89% (κ = 0.275). The overall agreement of T-SPOT.TB and QFN-G-IT with TST was 80.8% (κ = 0.019) and 89% (κ = 0.373), respectively. We have found negative IFN-γ assays results among 2 BCG-vaccinated HIV-infected individuals with a positive TST. In non BCG-vaccinated patients, QFN-G-IT and TST were positive in 5 cases (7.5%) and T-SPOT.TB in 7 (10.4%). In contrast, in BCG-vaccinated patients, only TST was positive in 4/8 (50%) of the cases. The differences obtained in the number of positive results between TST and both IFN-γ assays in BCG vaccinated patients were significant (95% CI 3-97%, p = 0.046), however, the confidence interval is very wide given the small number of patients. In patients with CD4< 200, we obtained only one (5%) positive result with T-SPOT.TB; however, QFN-G-IT and TST were negative in all cases. On the contrary, percentages of positive results in patients with CD4> 200 were 10.9% (6/55), 9.1% (5/55) and 16.4% (9/55) with T-SPOT.TB, QFN-G-IT and TST, respectively. Conclusions IFN-γ tests have the benefit over TST that are less influenced by BCG vaccination, consequently they are more specific than TST. Although our number of patients with advance immunosuppression is limited, our study suggests that IFN-γ assays are influenced with level of immunosuppression. The use of IFN-γ assays could be a helpful method for diagnosing LTBI in HIV population.

Published
2010
Full Text
View/download PDF

47. Eradication of hepatitis C virus and non-liver-related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection

Author

Berenguer, Juan, Rodríguez-Castellano, Elena, Carrero, Ana, Von Wichmann, Miguel A., Montero, Marta, Galindo, María J., Mallolas, Josep, Crespo, Manuel, Téllez, María J., Quereda, Carmen, Sanz, José, Barros, Carlos, Tural, Cristina, Santos, Ignacio, Pulido, Federico, Guardiola Tey, Josep Maria, Rubio, Rafael, Ortega, Enrique, Montes, María L., Jusdado, Juan J., Gaspar, Gabriel, Esteban, Herminia, Bellón, José M., González-García, Juan, and GESIDA HIV-HCV Cohort Study Group

Subjects
Male, Time Factors, Databases, Factual, Viral Hepatitis, Comorbidity, Hepacivirus, medicine.disease_cause, Gastroenterology, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, Fetge, Medicine, 030212 general & internal medicine, Virus de la Inmunodeficiencia Humana, Hígado, Coinfection, SIDA, Incidence, Hazard ratio, Middle Aged, Hepatitis C, Treatment Outcome, Liver, Regression Analysis, 030211 gastroenterology & hepatology, Original Article, Drug Therapy, Combination, Female, Human Immunodeficiency Virus, Adult, medicine.medical_specialty, 616.9, Hepatitis C virus, Virus de la Immunodeficiència Humana, VHC, Non–acquired immunodeficiency syndrome, Risk Assessment, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Diabetes mellitus, Internal medicine, Ribavirin, Mortalitat, Humans, Mortality, Retrospective Studies, Acquired Immunodeficiency Syndrome, Hepatology, business.industry, Proportional hazards model, Síndrome d’immunodeficiència no adquirida, HIV, Interferon-alpha, VIH, Original Articles, Hepatitis C, Chronic, medicine.disease, Survival Analysis, Síndrome de inmunodeficiencia no adquirida, chemistry, Spain, Immunology, Mortalidad, business, Follow-Up Studies
Abstract

We assessed non-liver-related non–acquired immunodeficiency syndrome (AIDS)-related (NLR-NAR) events and mortality in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV)–coinfected patients treated with interferon (IFN) and ribavirin (RBV), between 2000 and 2008. The censoring date was May 31, 2014. Cox regression analysis was performed to assess the adjusted hazard rate (HR) of overall death in responders and nonresponders. Fine and Gray regression analysis was conducted to determine the adjusted subhazard rate (sHR) of NLR deaths and NLR-NAR events considering death as the competing risk. The NLR-NAR events analyzed included diabetes mellitus, chronic renal failure, cardiovascular events, NLR-NAR cancer, bone events, and non-AIDS-related infections. The variables for adjustment were age, sex, past AIDS, HIV transmission category, nadir CD4+ T-cell count, antiretroviral therapy, HIV RNA, liver fibrosis, HCV genotype, and exposure to specific anti-HIV drugs. Of the 1,625 patients included, 592 (36%) had a sustained viral response (SVR). After a median 5-year follow-up, SVR was found to be associated with a significant decrease in the hazard of diabetes mellitus (sHR, 0.57; 95% confidence interval [CI], 0.35-0.93; P = 0.024) and decline in the hazard of chronic renal failure close to the threshold of significance (sHR, 0.43; 95% CI, 0.17-1.09; P = 0.075). Conclusion: Our data suggest that eradication of HCV in coinfected patients is associated not only with a reduction in the frequency of death, HIV progression, and liver-related events, but also with a reduced hazard of diabetes mellitus and possibly of chronic renal failure. These findings argue for the prescription of HCV therapy in coinfected patients regardless of fibrosis stage. (Hepatology 2017;66:344–356).

Published
2017

48. Association Between Visceral Abdominal Fat Accumulation and Severity of Liver Fibrosis in Nondiabetic Individuals Coinfected by Human Immunodeficiency Virus and Hepatitis C Virus.

Author

Soldevila, Laura, Tenesa, Montserrat, Horneros, Judith, Bechini, Jordi, López, Juan José, Pérez, Ricardo, Martínez, Miguel Àngel, Ouchi, Dan, Franco, Sandra, Perez-Àlvarez, Nuria, Buccione, Daniela, Clotet, Bonaventura, and Tural, Cristina

Abstract

Our primary objective was to assess the independent association between liver fibrosis (LF) and abdominal fat accumulation (AFA) and fatty liver disease (FLD). We also aimed to determine the diagnostic accuracy of AFA and FLD for the prediction of cirrhosis measured using unenhanced low-dose computed tomography (CT). This is a cross-sectional study in stable human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients with active HCV replication. CT was used to quantify fat content in segments III and VI of the liver and AFA. Transient elastometry was used to stage LF. Multivariate logistic regression, receiver operating characteristic curve analysis, and linear mixed model analysis were applied. One hundred fifteen HIV/HCV-coinfected patients were included. Cirrhosis was detected in 20.8% (24 patients). There was a high correlation between anthropometric characteristics and radiological variables. The factors independently associated with cirrhosis were albumin concentration [odds ratio (OR), 0.69; 95% confidence interval (CI), 0.58–0.83; p < .0001] and visceral fat accumulation (OR, 1.02; 95% CI, 1.01–1.04; p = .0003). Multinomial analysis showed that visceral fat area (VFA) was the factor independently associated with stage F2 (OR, 1.02; 95% CI, 1.0–1.03; p < .005) and albumin concentration with stage F3 (OR, 0.75; 95% CI, 0.64–0.89; p < .001). VFA was the only radiological variable with an area under the curve >0.7 for the prediction of cirrhosis. There was no inter- or intraobserver variability in the measurement of AFA; however, high interobserver variability was recorded in the measurement of FLD. The association of VFA with cirrhosis, the high reproducibility of CT for the measurement of VFA, and the ability of VFA to predict cirrhosis make CT a suitable technique for identifying HIV/HCV-coinfected patients for closer surveillance. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. Estimating the HIV undiagnosed population in Catalonia, Spain: descriptive and comparative data analysis to identify differences in MSM stratified by migrant and Spanish-born population.

Author

Reyes-Urueña, Juliana Maria, Campbell, Colin N. J., Vives, Núria, Esteve, Anna, Ambrosioni, Juan, Tural, Cristina, Ferrer, Elena, Navarro, Gemma, Force, Lluis, García, Isabel, Masabeu, Àngels, Vilaró, Josep M., García de Olalla, Patricia, Caylà, Joan Artur, Miró, Josep M., and Casabona, Jordi

Abstract

Objective Undiagnosed HIV continues to be a hindrance to efforts aimed at reducing incidence of HIV. The objective of this study was to provide an estimate of the HIV undiagnosed population in Catalonia and compare the HIV care cascade with this step included between high-risk populations. Methods To estimate HIV incidence, time between infection and diagnosis and the undiagnosed population stratified by CD4 count, we used the ECDC HIV Modelling Tool V.1.2.2. This model uses data on new HIV and AIDS diagnoses from the Catalan HIV/AIDS surveillance system from 2001 to 2013. Data used to estimate the proportion of people enrolled, on ART and virally suppressed in the HIV care cascade were derived from the PISCIS cohort. Results The total number of people living with HIV (PLHIV) in Catalonia in 2013 was 34 729 (32 740 to 36 827), with 12.3% (11.8 to 18.1) of whom were undiagnosed. By 2013, there were 8458 (8101 to 9079) Spanish-born men who have sex with men (MSM) and 2538 (2334 to 2918) migrant MSM living with HIV in Catalonia. A greater proportion of migrant MSM than local MSM was undiagnosed (32% vs 22%). In the subsequent steps of the HIV care cascade, migrants MSM experience greater losses than the Spanishborn MSM: in retention in care (74% vs 55%), in the proportion on combination antiretroviral treatment (70% vs 50%) and virally suppressed (65% vs 46%). Conclusions By the end of 2013, there were an estimated 34 729 PLHIV in Catalonia, of whom 4271 were still undiagnosed. This study shows that the Catalan epidemic of HIV has continued to expand with the key group sustaining HIV transmission being MSM living with undiagnosed HIV. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results